Corporate Information, English, IR, News, Other Corporate Information

Invitation to presentation of Acarix´s third quarter 2025 report

  • Posted by author-avatar
06 Nov

Acarix third quarter result is now released and we invite investors, analysts, and media representatives to join the recorded webcast presentation of the third quarter report for 2025. The presentation is led by CEO Aamir Mahmood and is conducted in English.

The report is found here : https://acarix.com/investor-presentations/

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 40,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). The Company’s Certified Adviser is Tapper Partners AB. For more information, please visit www.acarix.com

For more information, contact
Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments
Invitation to presentation of Acarix´s third quarter 2025 report

Invitation to presentation of Acarix´s third quarter 2025 report
Back to list
Older Acarix Publishes Interim Report, Third quarter 2025